Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday. The post Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout appeared first on Investor's Business Daily.
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.
The post Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
